# The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

Study · id `cardio:ct-nct01270191` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01270191](<https://clinicaltrials.gov/study/NCT01270191>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01270191

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT01270191. Randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT01270191, source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)
- Start date: 2010-11 (registry gives no type) (ClinicalTrials.gov record NCT01270191, source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)
- Primary completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01270191, source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01270191, source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT01270191, source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01270191-2013-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
- Condition: Type 2 Diabetes
- Intervention (Drug): Exenatide
- Intervention (Drug): Humulin-N
- Lead sponsor: Taipei Veterans General Hospital, Taiwan
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Taipei Veterans General Hospital, Taiwan (`cardio:org-taipei-veterans-general-hospital-taiwan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia (`cardio:pubmed-42290292`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a7f1478d6330da3881b35be1bedb7774d5914c487574cb125cb68ef5b209a0e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
